Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Two key players in immunology and vaccine innovation gain financial momentum as they push forward with mRNA vaccines …
Roche introduces an ultra-rapid and scalable next-generation sequencing method poised to accelerate genomic research and potentially reshape clinical …
The FDA has cleared vimseltinib (Romvimza), a first-in-class CSF1R inhibitor, for symptomatic tenosynovial giant cell tumor—marking a breakthrough …
Grace Therapeutics reports that its Phase III STRIVE-ON trial showed GTx-104 significantly reduces clinically significant hypotension and improves …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Arrowhead Pharmaceuticals’ NDA for plozasiran in rare, life-threatening FCS wins FDA acceptance, setting a PDUFA action date and …
Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
Already a subscriber? Log in